Examples of using Adjusted mean in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
Adjusted mean treatment increases from baseline in weighted mean 0-24 hours FEV1 of 341 mL(fluticasone furoate/vilanterol) and 377 mL(salmeterol/FP)
The adjusted mean change in the pain VAS after 12 weeks of tocilizumab treatment was a reduction of 41 points on a scale of 0- 100 compared to a reduction of 1 for placebo patients p< 0.0001.
HbA1c reductions were sustained through Week 102 -0.78% and 0.02% adjusted mean change from baseline for 10 mg and placebo, respectively.
HbA1c reductions were sustained through Week 102 -0.78% and 0.02% adjusted mean change from baseline for dapagliflozin 10 mg and placebo, respectively.
13.8), p=0.006, and with an adjusted mean change in CD4 count of 325 vs 281 cells/ mm3, respectively.
silodosin 8 mg once daily was shown to be non inferior to tamsulosin 0.4 mg once daily: the adjusted mean difference(95% CI) in the IPSS Total Score between treatments in the per-protocol population was
The key secondary endpoint of adjusted mean change from baseline in weekly RFBMs was 3.1 in the methylnaltrexone bromide 12 mg once daily treatment group,
Adjusted mean change of trough seated diastolic blood pressure(SeDBP) was as follows.
In the extension period, HbA1c reductions were sustained through Week 102 -0.61%, and -0.17% adjusted mean change from baseline for dapagliflozin 10 mg and placebo, respectively.
Fluticasone furoate/vilanterol 92/22 micrograms increased adjusted mean weighted mean FEV1 over 0-4 hours by 148 ml compared to FF alone 95% CI: 112, 184 mL, p< 0.001.
Adjusted mean change of trough seated diastolic blood pressure(SeDBP) was as follows: 3.8 mm Hg(low dose),
Improvements were also seen in this subgroup at week 52 when comparing the fluticasone furoate/vilanterol 92/22 micrograms vs. vilanterol 22 micrograms in adjusted mean trough FEV1 44 mL 95% CI:
Adjusted mean treatment increases from baseline in weighted mean 0-24 hours FEV1 of 130 mL(fluticasone furoate/vilanterol) and 108 mL(salmeterol/FP) demonstrated an overall
showed a greater reduction in disease activity for tocilizumab compared to placebo adjusted mean changes of -45.2 mm vs -35.2 mm, p=0.0031.
Linagliptin in combination with metformin plus insulin provided significant improvements in HbA1c in this subgroup with -0.68%(CI: -0.78; -0,57) adjusted mean change from baseline(mean baseline HbA1c 8.28%)
HZC102871 at week 52, an improvement was seen when comparing the fluticasone furoate/vilanterol 92/22 micrograms versus vilanterol 22 micrograms in adjusted mean trough FEV1 42 mL 95% CI:
In a pre-specified analysis of subjects with baseline HbA1c≥ 9.0%, treatment with dapagliflozin 10 mg resulted in statistically significant reductions in HbA1c at Week 24 as an add-on to metformin adjusted mean change from baseline: -1.32% and -0.53% for dapagliflozin and placebo.
fluticasone furoate/vilanterol 92/22 micrograms resulted in a significantly lower annual rate of moderate/severe COPD exacerbations compared with vilanterol adjusted mean annual rates of 0.83
The adjusted mean change from baseline in trough FEV1 on Day 85 was 111 mL in the fluticasone furoate/vilanterol group
The adjusted mean dietary phenylalanine tolerance in the Kuvan plus phenylalanine-restricted group was 80.6 mg/kg/day and was statistically significantly greater(p< 0.001) than the adjusted mean dietary phenylalanine tolerance in dietary phenylalanine therapy alone group 50.1 mg/kg/day.